Ticker Details
Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH).
IPO Date:	February 6, 2007
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$11.93B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$4.01 | 2.53%
Avg Daily Range (30 D):	$7.89 | 1.51%
Avg Daily Range (90 D):	$8.12 | 1.67%

Institutional Daily Volume
Avg Daily Volume:	.15M
Avg Daily Volume (30 D):	.23M
Avg Daily Volume (90 D):	.27M

Trade Size
Avg Trade Size (Sh.):	41
Avg Trade Size (Sh.) (30 D):	21
Avg Trade Size (Sh.) (90 D):	23

Institutional Trades
Total Institutional Trades:	2,589
Avg Institutional Trade:	$7.31M
Avg Institutional Trade (30 D):	$17.56M
Avg Institutional Trade (90 D):	$18.43M
Avg Institutional Trade Volume:	.03M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$7.91M
Avg Closing Trade (30 D):	$18.18M
Avg Closing Trade (90 D):	$19.87M
Avg Closing Volume:	33.62K

News

Apr 22, 2026 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: Na

Apr 1, 2026 @ 12:49 AM The $578 Billion Regenerative Medicine Market Has ... Source: Usa News Group

Mar 25, 2026 @ 9:24 PM Prediction: 2 Stocks That Will Be Worth More Than ... Source: Prosper Junior Bakiny

Mar 21, 2026 @ 11:19 PM This New $193 Million Bet Targets a Biotech With $... Source: Jonathan Ponciano

Feb 11, 2026 @ 10:00 AM Madrigal Expands its MASH Pipeline with Exclusive ... Source: Na

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-3.25	$-2.53	$-12.85
Diluted EPS	$-3.25	$-2.53	$-12.85
Revenue	$311.34M	$321.08M	$958.4M
Gross Profit
Net Income / Loss	$-94.39M	$-58.58M	$-288.28M
Operating Income / Loss	$-92.72M	$-59.61M	$-300.1M
Cost of Revenue
Net Cash Flow	$27.09M	$-96.92M	$98.75M
PE Ratio

Splits
Jul 25, 2016	1:35